alexa Aviscumine (ME-503)-Skin Reaction as significant Factor
ISSN: 2471-9552

Immunotherapy: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma

Uwe Trefzer1, Ralf Gutzmer2, Tabea Wilhelm3, Florian Schenck4, Katharina C. Kähler5, Volkmar Jacobi6, Klaus Witthohn7, Hans Lentzen7* and Peter Mohr8

1Dermatologikum Berlin, Germany

2Klinik für Dermatologie, Allergologie und Venerologie. Hauttumorzentrum Hannover (HTZH), Hannover Germany

3Charité-Universitätsmedizin Berlin, Hauttumorzentrum Charité (HTCC), Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany

4Hautärzte Zentrum Hannover, Germany

5Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein-Campus Kiel, Germany

6Institut für Diagnostische Radiologie , Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt/Main, Germany

7MELEMA Pharma GmbH, Hamburg, Germany

8Elbe-Klinikum Buxtehude, Dermatologisches Zentrum Buxtehude, Germany

*Corresponding Author:
Hans Lentzen
MELEMA Pharma GmbH, Hamburg, Germany
E-mail: [email protected]

Received date: January 07, 2017; Accepted date: January 30, 2017; Published date: February 13, 2017

Citation: Trefzer U, Gutzmer R, Wilhelm T, Schenck F, Kähler KC, et al. (2017) Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma. Immunother Open Acc 3: 135. doi:10.4172/2471-9552.1000135

Copyright: © 2017 Trefzer U, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Aviscumine (ME-503), a recombinant lectin, enhances inflammatory cytokine (esp. IL-1β) release, activation of Langerhans cells, and T-cell responses. An extended evaluation of phase II data of the patient cohorts with/without skin reactions within the first treatment cycle after SC injection regarding the efficacy of aviscumine are presented. 31 patients (ITT total population) (ECOG: 0 or 1) with progressive stage IV malignant melanoma after failure of standard therapy were enrolled onto a single-arm, multi-centre, open-label, phase II trial (NCT00658437). Patients received 350 ng aviscumine twice weekly by SC injection until progression. Tumor response was assessed every eight weeks, survival of patients was followed up to one year after the end of therapy. 21 patients with skin reactions vs. 9 patients without skin reactions as adverse events were assessed for efficacy in an expanded evaluation. Comparing the median overall survival data (mOS) in patients (n=9) without injection site reactions (mOS: 5.1 months; 95% CI 2.1-6.9; 1-year survival rate: 0%) with survival data in patients (n=21) showing injection site reactions (mOS: 14.6 months; 95% CI 11.0-19.8; 1-year survival rate: 62%) a clear difference in favor of the patients with skin reactions is seen. The difference in overall survival between these two groups of patients was high significant (p<0.0001). In the total ITT population (n=31) the mOS was 11.0 months (95% CI 6.9-19.8) and the 1- year survival rate was 45%. Preliminary conclusions from our small cohorts suggest a strong clinical impact of aviscumine in patients with previously treated metastatic melanoma if those patients show injection site reactions as adverse events after SC injection within the first treatment cycle. Patients without any injection site reactions apparently failed to prove clinical benefit.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords